1. Spain Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Faes Farma, S.A.

Faes Farma, S.A.

4.71
EUR
-0.03
(-0.63%)
1.08BMarket Cap
Feb 26Next Earn
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
0.75
0.75
0.78
0.88
1.02
1.17
1.26
1.31
1.32
1.44
1.46
1.59
1.96
- -
Basic EPS, GAAP
0.09
0.1
0.12
0.14
0.15
0.19
0.23
0.25
0.27
0.29
0.3
0.36
0.26
- -
Free Cash Flow per Basic Share
0.11
0.11
0.12
0.14
0.09
0.14
0.16
0.18
0.07
0.09
- -
0.24
0.18
- -
Dividend per Share
- -
- -
0.02
0.02
0.02
0.03
0.04
0.04
0.05
0.06
0.05
0.16
0.18
- -
Book Value per Share
0.88
0.95
1
1.09
1.19
1.3
1.45
1.62
1.76
1.89
2.13
2.33
2.39
2.33
Tangible Book Value per Share
0.41
0.54
0.63
0.75
0.58
0.7
0.85
1.05
1.16
1.33
1.53
1.74
0.92
1.74
Basic Weighted Avg Shares
242
254
261
261
268
276
284
291
303
306
310
311
311
311
Sales/Revenue/Turnover
180
192
205
229
275
324
357
380
399
439
451
494
610
- -
Operating Margin (%)
16.14
18.96
20.37
21.1
18.1
19.29
22.23
24.35
24.55
23.3
23
22.3
14.92
- -
Depreciation Expense
8
6
6
6
8
10
13
15
17
19
19
20
29
- -
Net Income, GAAP
23
25
30
37
41
52
64
73
82
89
92
111
80
- -
Effective Tax Rate (%)
6.58
22.65
22.61
20.57
16.2
16.09
13.68
13.56
11.32
11.81
10.85
- -
6.73
- -
Profit Margin (%)
12.53
13.21
14.83
16
15.07
15.91
17.9
19.08
20.67
20.4
20.37
22.56
13.04
- -
Working Capital
34
59
82
116
113
114
151
205
214
219
203
230
298
230
LT Debt
21
5
- -
- -
43
1
3
2
2
4
4
3
378
3
Total Equity
198
229
254
285
320
360
414
473
537
602
663
727
746
727
Return on Invested Capital (%)
9.91
10.71
12.11
13.33
12.84
13.27
15.38
16.4
15.92
15.07
13.8
- -
8.59
- -
Return on Capital (%)
9.95
10.85
12.35
13.5
12.63
13.18
15.2
15.72
15.86
15.1
13.98
- -
8.86
- -
Return on Common Equity (%)
11.82
11.88
12.57
13.57
13.69
15.19
16.55
16.41
16.36
15.74
14.55
16.04
10.83
- -

Capital Structure

EUR

•

in mil. unless spec.
Mar'24
Jun'24
Dec'24
ST Debt
- -
40
20
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
4
3
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
311
311
311
Market Capitalization
979
1,122
1,083

Working Capital

EUR

•

in mil. unless spec.
Mar'24
Jun'24
Dec'24
Total Current Assets
- -
347
334
Cash, Cash Equivalents & STI
- -
70
72
Accounts Receivable, Net
- -
138
111
Inventories
- -
139
142
Total Current Liabilities
- -
127
103
Payables & Accruals
- -
- -
- -
ST Debt
- -
40
20
Deferred Revenue
- -
- -
- -

Growth Rates

EUR

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
11.41%
9.6%
2.61%
Free Cash Flow
-640.16%
-1,295.91%
-27.72%
Net Income, GAAP
11.33%
3.51%
-28.49%
Sales/Revenue/Turnover
11.73%
10.16%
23.66%
Total Cash Common Dividend
37.46%
55.48%
15.49%

Semi-annual Revenue

EUR

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
494
2025
- -
314
610
2026
- -
- -
- -

Semi-annual Earnings Per Share

EUR

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
0.36
2025
- -
0.09
0.26
2026
- -
- -
- -

Semi-annual Dividends Per Share

EUR

•

in mil. unless spec.

Year

H1
H2
FY
2024
- -
- -
0.16
2025
- -
- -
0.18
2026
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Eduardo Recoder de la Cuadra
Full Time Employees
2,611
Sector
Health technology
Industry
Pharmaceuticals: major
Address
Avenida Autonomía 10 Leioa BQ Spain 48940
IPO Date
Mar 25, 1994
Website
faesfarma.com
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Faes Farma, S.A. (FAE.MC) researches, develops, manufactures and markets pharmaceutical products, healthcare specialties, animal nutrition and health solutions, and pharmaceutical raw materials worldwide. The company operates through Pharmaceutical and Healthcare Specialties; Animal Nutrition and Health; and Pharmaceutical Raw Materials segments, offering prescription and generic drugs including the proprietary molecules bilastine for allergies, calcifediol for vitamin D treatments, and mesalazine for gastroenterology; over-the-counter medicines, food supplements and personal care treatments targeting allergies, venous insufficiency, irritable bowel syndrome, bone health, pain relief and immunology; animal nutrition products such as specialized feeds for swine and other species through the FARM Faes division and subsidiaries including Ingaso Farm, Tecnovit and Capselos; and active pharmaceutical ingredients. Faes Farma conducts significant R&D investment, exports to more than 130 countries and maintains direct operations in Europe including Spain, Portugal and Italy, Latin America encompassing Mexico, Colombia, Chile, Peru, Ecuador and Guatemala, as well as Africa and the Middle East; it employs around 1,775 people with headquarters, production facilities and R&D center in Leioa, Spain, additional offices in Madrid and Barcelona, and a new 60,000 square meter plant in Derio completed in 2024 to triple production capacity to 100 million units annually by 2027. Founded in 1933, the company listed on the Madrid Stock Exchange in the 1940s and pursues international expansion through strategic acquisitions including Laboratorios Edol, a Portuguese ophthalmology firm, for 75 million euros in March 2025 to double sales in Portugal; SIFI, an Italian ophthalmic specialist, for 270 million euros in September 2025, its largest deal and elevating ophthalmology to nearly 20 percent of revenues; and earlier purchases of Initial Technical Foods in 2017 alongside diversification into animal nutrition via Ingaso in 2007; it also advances new offerings such as high-dose metocarbamol tablets for pain relief, mesalazina granules clinical trials, iFEROL vitamin D analogues in 2025, alongside investments in a 150 million euro Huesca facility for animal feed aiming to double that segment's revenues by 2027-2028.